High Glycolytic Activity Signature Reveals CCNB2 as a Key Therapeutic Target in Triple-Negative Breast Cancer
Frontiers in Bioscience-Landmark · 2024
DOI: 10.31083/j.fbl2908308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Jing Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of Henan University of Science and Technology, 471003 Luoyang, Henan, China. Hauptthemen laut MEDLINE: Glycolysis, Cyclin B2, Triple Negative Breast Neoplasms, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for Henan University of Science and Technology, A-type Doctoral Talent Project of Henan University of Science and Technology.
Abstract (Originalsprache)
Background
Aerobic glycolysis and the cell cycle are well-established tumor hallmarks. Understanding their relationship could help to unravel the pathogenic mechanisms of breast cancer (BC) and suggest potential new strategies for treatment.
Methods
Glycolysis-related genes (GRGs) were downloaded from the Reactome database and screened using univariate Cox analysis. The consensus clustering method was employed to identify a glycolytic activity signature (GAS) using the Gene Expression Omnibus (GEO) dataset. A nomogram risk prediction model was constructed using coefficients from univariate Cox analysis. Immune cell infiltration was evaluated using single-sample gene set enrichment analysis (ssGSEA) and the ESTIMATE algorithm. Gene co-expression modules were created using weighted correlation network analysis (WGCNA) to identify hub genes. Gene expression in three BC cell lines was quantified using Quantitative Reverse Transcriptase Polymera (qRT-PCR). Single-cell RNA sequencing (scRNA-seq) data was used to examine the relationship between GAS and hub genes. The sensitivity of different groups to cell cycle-related clinical drugs was also examined.
Results
BC with high GAS (HGAS) showed high tumor grade and recurrence rate. HGAS was a prognostic indicator of worse overall survival (OS) in BC patients. HGAS BC showed more abundant immune cells and significantly higher expression of immunomodulators compared to BC with low GAS (LGAS). HGAS BC also showed enhanced cell cycle pathway, with high mRNA and protein expression levels of Cyclin B2 (CCNB2), a key component of the cell cycle pathway. Importantly, scRNA-seq analysis revealed that elevated CCNB2 expression was positively correlated with HGAS in triple-negative BC (TNBC). This was validated in clinical samples from TNBC patients. High expression of CCNB2 was found in three BC cell lines, and was also an indicator of poor prognosis. HGAS BC showed high sensitivity to several cell cycle-related clinical drugs, with 9 of these also showing activity in BC with high CCNB2 expression.
Conclusions
HGAS was associated with enhanced cell cycle pathway and immune activity in BC. These results suggest that CCNB2 is a potential key therapeutic target in BC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First Affiliated Hospital of Henan University of Science and Technology, 471003 Luoyang, Henan, China.
- Precision Medicine Laboratory, School of Medical Technology and Engineering, Henan University of Science and Technology, 471003 Luoyang, Henan, China.
- Henan Engineering Research Center of Digital Pathology and Artificial Intelligence Diagnosis, The First Affiliated Hospital of Henan University of Science and Technology, 471003 Luoyang, Henan, China.
- Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 330008 Nanchang, Jiangxi, China.
Förderung
- Fundamental Research Funds for Henan University of Science and Technology
- A-type Doctoral Talent Project of Henan University of Science and Technology
Zitieren
APA
Liang, J., Ma, H., Zhang, S., Dong, Y., Zheng, J., Zeng, L., Xiong, X., Huang, W., Yin, Q., & Zheng, X. (2024). High Glycolytic Activity Signature Reveals CCNB2 as a Key Therapeutic Target in Triple-Negative Breast Cancer. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2908308
Vancouver
Liang J, Ma H, Zhang S, Dong Y, Zheng J, Zeng L, et al. High Glycolytic Activity Signature Reveals CCNB2 as a Key Therapeutic Target in Triple-Negative Breast Cancer. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2908308
BibTeX
@article{Liang2024,
author = {Liang, Jing and Ma, Haodi and Zhang, Shunshun and Dong, Yirui and Zheng, Jiayu and Zeng, Li and Xiong, Xin and Huang, Wenbin and Yin, Qinan and Zheng, Xuewei},
title = {High Glycolytic Activity Signature Reveals CCNB2 as a Key Therapeutic Target in Triple-Negative Breast Cancer},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
doi = {10.31083/j.fbl2908308}
}
EUVIMED